Potato Ingestion and Time-trial Performance

October 7, 2019 updated by: University of Illinois at Urbana-Champaign

Ingestion of Potatoes as a Nutritional Strategy to Improve Cycling Time-trial Performance in Endurance Trained Cyclists

This research study evaluates the feasibility and appropriateness of potatoes as an ergogenic aid in comparison to the currently promoted sports gels during a cycling challenge and time trial. Using a crossover design, trained cyclists will complete three separate cycling challenges and subsequent time trials in which they will consume either potatoes, commercially available sports gels, or water only.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The metabolic demands created by endurance activities, which include muscle and liver glycogen depletion as well as losses in body fluids and electrolytes, are significant limitations to the performance potential of the athlete. For this reason, a well-supported recommendation exists for such athletes to consume a carbohydrate formula, in particular, one containing electrolytes during their activity.

Currently, most commercially available exercise-nutrition products for use in endurance activities come at relatively high costs to the athlete. Moreover, the ingredients used within this market vary and could therefore hinder their effectiveness. For example, Fermentable Oligosaccharides Disaccharides Monosaccharides and Polyols (FODMAPs) potentially present in common sports foods (i.e. excess fructose) are known to alter gastrointestinal (GI) function in some individuals. Indeed, 25-70% of endurance athletes experience GI symptoms during exercise. Given the prevalence of exercise induced GI discomfort in this population, it is possible that GI symptoms limit the adherence to nutritional recommendations during exercise. Therefore identification of a targeted nutrition strategy that maximizes GI effectiveness and dietary adherence is warranted.

An alternative to the commercially available sports foods are whole foods. Specifically, white potatoes, which have a high GI index, indicates that their carbohydrate content is readily available. Additionally, potatoes naturally contain potassium, an important electrolyte. Because of these characteristics, potatoes provide the potential to be a low-cost alternative, and merit investigation. To this point, we know of no studies that have explored the effectiveness of white potatoes as an ergogenic aid. Therefore, the purpose of this study is to examine how capable potatoes are at off-setting the losses in muscle and liver glycogen and electrolytes compared to the current products available on the market, i.e. "sports gels."

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
12

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Illinois
      • Urbana, Illinois, United States, 61801
        • Freer Hall

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

20 years to 40 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female
  • ≥150 km/wk of cycling mileage
  • ≥6 months of prior training history
  • VO2peak values ≥45 ml/kg/min for females and ≥50 ml/kg/min for males
  • Aged between 20-40 years

Exclusion Criteria:

  • Chronic Smoking or tobacco use
  • Active cardiovascular disease
  • Diabetes Mellitus or other metabolic disorders
  • Liver kidney, or urinary disease
  • Musculoskeletal/Orthopedic disorders (e.g., osteoarthritis, rheumatoid arthritis, tendinitis, gout, fibromyalgia, patellar tendinopathy, or chronic low back pain)
  • Neuromuscular disorders
  • hypertension
  • Diagnosed GI tract diseases
  • Heart Disease
  • Bleeding or clotting disorders
  • Neurological disease
  • Epilepsy
  • Respiratory disease
  • Pregnancy
  • Contraindications for exercise
  • <150 km/wk of cycling mileage
  • <6 months of prior training history
  • VO2peak values <45 ml/kg/min for females and <50 ml/kg/min for males

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Trial 1
Water Intervention: In one of the 3 cycling trials, participants will receive only water and no carbohydrate supplementation during the 2 hour cycling challenge.
Dietary supplement: Water
Water will be used as a control during one of the three cycling challenges (participants will not receive any carbohydrate supplementation).
Other Names:
  • Control
Experimental: Trial 2
Carbohydrate Gel Intervention: In one of the 3 cycling trials, participants will receive carbohydrate supplementation in the form of commercially available gels (15g every 15 minutes) during the 2 hour cycling challenge.
Dietary supplement: Carbohydrate Gel
Commercially available PowerBar PowerGel will be used for the carbohydrate gel condition during one of the three cycling challenges.
Experimental: Trial 3
Potatoes Intervention: In one of the 3 cycling trials, participants will receive carbohydrate supplementation in the form of pureed russet potato (15g every 15 minutes) during the 2 hour cycling challenge.
Dietary supplement: Potatoes
Pureed russet potatoes will be used as a carbohydrate supplement for participants during one of the three cycling challenges.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Time trial performance measured in minutes
Time Frame: 1 year
Comparison of time trial performance times between potatoes and sports gel conditions to determine effectiveness of potatoes as an ergogenic aid.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Illinois at Urbana-Champaign

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Alliance for Potato Research and Education

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Nicholas A Burd, Ph.D, University of Illinois at Urbana-Champaign, Department of Kinesiology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 29, 2017

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 29, 2019

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 29, 2019

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 19, 2017

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 21, 2017

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 27, 2017

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 9, 2019

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 7, 2019

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2017

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 18104

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Exercise Performance

Clinical Trials on Water

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings